StockData
NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW

NeuroSense Therapeutics Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$2.67−0.40 (-13.19%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
–
Dividend yield
–

NeuroSense Therapeutics Ltd. revenue by segment

No segment breakdown reported

NeuroSense Therapeutics does not break out revenue by segment, region or product in the tagged data of its filings for this period type.